Immunovaccine Highlights Enhanced Anti-Tumor Activity of Cancer Vaccine Combination Therapies in Presentation at the 2014 AACR Annual Meeting

Study findings show enhanced therapeutic potential for vaccine when combined with cyclophosphamide and the checkpoint inhibitor anti-PD-1 April 7, 2014 Immunovaccine Inc., a clinical stage vaccine company, presented positive data from clinical and preclinical vaccine studies, including DPX-Survivac, the company’s lead therapeutic cancer vaccine, this weekend at the American Association for Cancer Research (AACR) 2014 Annual Meeting. In a poster …